Designing Longevity
Skip to main content
Brand-name GLP-1Compounded GLP-1

Ro

Program terms need a fresh check

Edited by Designing Longevity Editorial · earlier profile checked May 1, 2026

Current program terms need a fresh check. Request a written care and medication quote. Earlier public-record dates are shown below.

Program terms need a fresh check. Ask Ro for a written quote covering care, medication, billing and cancellation. The dated public-record details remain below.

Reviews of individual programs

Program reviews cover their own costs, terms and support. The program-terms checklist applies to the named care program, not every service offered by this company.

Ro GLP-1 program review

Program costs and payment terms

Current program terms need a fresh check. Get a written price and billing quote directly before paying.

Membership
Current membership price needs a fresh check.
Insurance
Insurance terms need a fresh check; confirm directly before paying.

Designing Longevity is a founder-led editorial publication. Our content is not medically reviewed.

The full profile and rubric were last checked May 1, 2026. Current commercial terms above have their own check date; they do not refresh earlier ratings or clinical claims.

Read the earlier full profile and source record (May 1, 2026)

This record keeps its original check dates. The program-terms checklist above covers costs, billing and advertised support for the named care program.

Earlier editorial take

Earlier review: best for

  • Patients who want one platform for multiple verticals

    Ro covers weight loss, men's health, hair loss, fertility, and skincare. If you'd rather use one provider for several needs, Ro is the most credible multi-vertical option.

  • Users who value mature support infrastructure

    Largest user base in the cohort and longest tenure means the operation is well-rehearsed.

Our take

The full profile retains its earlier verification date. Check the dated program terms below before choosing.

Pros

  • Both brand-name (, , ) and options
  • Established platform with mature support and largest user base in cohort
  • Accredited since 2018 (B rating)
  • review volume (21,800+) is the largest signal in our cohort and skews positive (4.4/5)

Cons

  • April 2025 FDA finasteride alert reflects on Ro's compounder-vendor track record
  • sourcing less transparent than vertically-integrated competitors

Pricing

Current pricing needs a fresh check.

Turnaround

Same-day Rx after async intake

States served

All 50

Earlier full review checked

May 1, 2026

Earlier rubric breakdown

How the earlier rating was scored

Licensure

20% weight
4.0/5

License and enforcement records checked at the profile verification date.

Active multi-state licensure across 50 states; no specifically on Ro at capture date. Counterweight: April 2025 FDA safety alert on topical finasteride explicitly applies to compounders and telemedicine platforms, and Ro markets compounded topical finasteride, so the alert reflects on the company even though Ro wasn't named.

Evidence checked in the earlier review (4)

  • Roman Health Ventures, Inc. (operating entity)

    Business filing

    Long-established corporate parent; founded 2017 as Roman, rebranded to Ro.

    Checked May 1, 2026

  • No FDA warning letter on Ro / Roman Health Ventures

    Federal database

    Verified against the FDA warning-letter database at capture date. None on record.

    Checked May 1, 2026 · source

  • April 2025 FDA safety alert on compounded topical finasteride (industry-wide)

    Federal alert

    FDA alert dated April 25, 2025 cites adverse events including suicidal ideation, depression, and erectile dysfunction tied to topical finasteride. Ro markets compounded topical finasteride for hair loss, so the alert reflects on the company even though Ro is not named.

    Checked May 1, 2026 · source

  • Active multi-state licensure

    State licensure

    Ro operates across all 50 states via licensed clinicians in each jurisdiction.

    Checked May 1, 2026

Accreditation

20% weight
4.0/5

Accreditation records checked at the profile verification date.

Accredited since July 23, 2018 with a B rating, among the longest-tenured BBB-accredited telehealth platforms. not independently confirmed on a public-registry URL at capture date (LegitScript doesn't publish a per-merchant directory); Ro advertises on Google and Meta, which generally requires LegitScript certification, so it's a strong inference.

Evidence checked in the earlier review (3)

  • BBB Accredited Business since July 23, 2018

    Accreditation

    Current rating: B. Long-tenured accreditation is itself a positive signal.

    Checked May 1, 2026 · source

  • LegitScript Healthcare Merchant Certification

    Accreditation

    Inferred from Ro's active Google and Meta advertising (which requires ), but LegitScript does not publish a public per-merchant directory URL we could confirm against.

    Checked May 1, 2026 · source

  • PCAB on partner compounding pharmacies

    Partner accreditation

    Ro uses partner compounding pharmacies for ; specific partner accreditations not publicly disclosed at fill level.

    Checked May 1, 2026

Transparency

20% weight
3.5/5

Published testing, sourcing, and formulation information.

sourcing details (which or partner) less granular than vertically-integrated competitors like Eden.

Evidence checked in the earlier review (2)

  • Compounded source pharmacy named per fill

    Sourcing

    Ro uses a network of compounding partners; specific partner per fill is not surfaced publicly.

    Checked May 1, 2026

  • "Compounded medications are not FDA-approved" disclosure published

    Compliance disclosure

    Checked May 1, 2026

Product quality

15% weight
3.5/5

Published testing, recall, and supply-chain information.

This earlier product-quality score has not been refreshed. The commercial update does not recheck manufacturing, sourcing or clinical care.

Evidence checked in the earlier review (4)

  • No FDA recalls on Ro-distributed GLP-1 product

    Recall history

    Checked May 1, 2026 · source

  • Branded GLP-1 supply via authorized distribution

    Sourcing

    , , and dispensed through standard pharmaceutical supply chain.

    Checked May 1, 2026

  • Compounded GLP-1 third-party lot testing program

    Testing

    Specific testing programs at partner pharmacies not publicly detailed at the per-fill level.

    Checked May 1, 2026

  • Compounder-vendor management (cross-product line)

    Vendor oversight

    April 2025 FDA finasteride alert applies to compounders and telemedicine platforms; Ro's topical finasteride line is in scope. Indicates a compounder-vendor track record that warrants scrutiny across product lines.

    Checked May 1, 2026 · source

Pricing

15% weight
3.0/5

Value within the category, no surprise fees, refund policy.

Current pricing needs a fresh check.

Customer service

10% weight
3.5/5

Refund policy, support quality, complaint history.

Wide review-platform split: 3.7/5 across ~3,200, B rating accredited since 2018, 4.4/5 across ~21,800. The ConsumerAffairs volume is significant (far larger sample than Trustpilot) and skews more positive.

Evidence checked in the earlier review (3)

  • Trustpilot rating: 3.7/5 across 3,198 reviews

    External review

    Checked May 1, 2026 · source

  • ConsumerAffairs rating: 4.4/5 across 21,848 reviews

    External review

    Largest external review sample in our cohort; meaningfully more positive than .

    Checked May 1, 2026 · source

  • Adverse-event reporting path documented

    Safety

    Checked May 1, 2026

Public reviews

What we found across third-party review platforms. These are external sentiment signals, not our scoring inputs.

Trustpilot

3.7 stars across 3,198 reviews, "Average" per 's banding. Strongest themes: convenience, ease of use, professional support. Negatives concentrate on cancellation friction and surprise charges.

Captured May 1, 2026Source

Better Business Bureau

Accredited since July 23, 2018; current rating B. Telemedicine business in New York, NY. Complaint patterns: misleading headline pricing (membership vs medication), unexpected charges, refund difficulties on cancellation.

Captured May 1, 2026Source

ConsumerAffairs

Markedly more positive than or : 4.4/5 across 21,848 reviews. Largest review sample in our cohort by an order of magnitude. The split between platforms is wide enough to weigh both: volume is meaningful, BBB pattern is also meaningful.

Captured May 1, 2026Source

Regulatory & legal history

FDA enforcement actions, manufacturer lawsuits, recalls, and other notable events on the public record.

  1. FDA Warning LetterApril 25, 2025

    FDA safety alert on topical finasteride products cites 32 reports of adverse events between 2019-2024, including suicidal ideation, anxiety, depression, erectile dysfunction, and persistent symptoms after discontinuation. The alert applies to compounders and telemedicine platforms; Ro markets compounded topical finasteride for hair loss and is in scope even though not named in the alert.

    Source

What to expect

  1. 1

    Pharmacy fulfillment

    3-7 days

    Approved routes to either an in-network pharmacy (branded) or a partner compounding pharmacy (). Cold-chain shipping handled by the fulfilling pharmacy.

Accreditations

State pharmacy/clinic license

Verified · May 1, 2026

LegitScript Certified

Unverified · May 1, 2026 · source

Frequently asked

What does Ro charge for membership?

Current membership price needs a fresh check.

Does Ro accept insurance?

Insurance terms need a fresh check; confirm directly before paying.

Is Ro the same as Roman?

Yes. Ro was founded in 2017 as Roman, focused on men's health (ED, hair loss). The company rebranded to Ro and expanded into multiple verticals including weight loss (Ro Body), women's health, fertility, and dermatology. Operating entity is Roman Health Ventures, Inc., based in New York.

Is Ro BBB-accredited?

Yes. Ro has been Accredited since July 23, 2018 with a current rating of B. The profile is at https://www.bbb.org/us/ny/new-york/profile/telemedicine/ro-0121-173581 if you want to read complaints directly. Long-tenured BBB accreditation is itself a positive signal.

Why is Ro flagged for the FDA finasteride alert?

On April 25, 2025, the FDA issued a safety alert about topical finasteride products, citing 32 reports of adverse events including suicidal ideation, anxiety, and persistent symptoms after discontinuation. The alert explicitly applies to compounders and telemedicine platforms. The FDA didn't name Ro specifically, but Ro markets compounded topical finasteride for hair loss, so the alert reflects on the company's compounder-vendor management even though it's a different product line from .

Update history

Every meaningful change to this profile, with a date stamp. We don't silently re-score.

  1. May 1, 2026

    Initial published profile. Sources HEAD-checked at publish time. Score reflects honest math after surfacing the April 2025 FDA finasteride alert (industry-wide but applies to Ro's product mix), the complaint pattern around membership-vs-medication billing transparency, and the wide review-platform split ( 3.7 vs 4.4 vs BBB B). Insurance concierge for branded remains the genuine differentiator.

Edited by Designing Longevity Editorial. Earlier profile checked May 1, 2026.

Spot something out of date or wrong? Let us know and we'll re-check.

Back to all providers